SAB Biotherapeutics, Inc.
SABS
$2.23
$0.3518.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.28M | -34.11M | -45.57M | -40.32M | -39.87M |
| Total Depreciation and Amortization | 3.59M | 4.79M | 4.95M | 4.97M | 4.81M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.19M | -2.68M | 3.25M | 2.70M | 5.45M |
| Change in Net Operating Assets | 1.54M | -2.30M | -842.00K | -4.43M | -4.66M |
| Cash from Operations | -31.34M | -34.29M | -38.21M | -37.08M | -34.26M |
| Capital Expenditure | -208.20K | -337.30K | -349.80K | -334.80K | -305.00K |
| Sale of Property, Plant, and Equipment | 500.00 | -- | 0.00 | 44.50K | 44.50K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.28M | -11.63M | -21.01M | -19.96M | -31.23M |
| Cash from Investing | 24.07M | -11.96M | -21.36M | -20.25M | -31.49M |
| Total Debt Issued | 516.00K | 516.00K | 765.20K | 765.20K | 765.20K |
| Total Debt Repaid | -1.35M | -1.42M | -1.44M | -929.80K | -1.04M |
| Issuance of Common Stock | 0.00 | 20.40K | 59.68M | 59.68M | 59.68M |
| Repurchase of Common Stock | -27.00K | -24.90K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 7.50M | 7.50M | 7.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -93.70K | -261.10K | -261.10K | -236.10K | -167.40K |
| Cash from Financing | -952.10K | -1.17M | 66.25M | 66.78M | 66.74M |
| Foreign Exchange rate Adjustments | -170.40K | -241.20K | 65.60K | 18.10K | -10.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.39M | -47.67M | 6.75M | 9.47M | 974.10K |